Card image cap
Covovax gets DCGI’s EUA nod for 12-17-year-olds

The drug regulator has given emergency approval to Serum Institute of India’s Covovax for use in children aged 12-17 years.  This is the fourth vaccine to get regulatory approval for use in youngsters.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment